Results 151 to 160 of about 81,008 (204)
Some of the next articles are maybe not open access.

RANKL biology

Bone, 2022
Since the receptor activator of nuclear factor-kappa B ligand (RANKL), its cognate receptor activator of nuclear factor-kappa B (RANK), and the decoy receptor osteoprotegerin (OPG) were discovered, a number of studies have uncovered the crucial role of the RANKL-RANK-OPG pathway in controlling the key aspect of bone homeostasis, the immune system ...
Noriko, Takegahara   +2 more
openaire   +2 more sources

RANKL and periodontitis

Folia Pharmacologica Japonica, 2023
Periodontal disease is characterized by inflammation of the periodontal tissue and subsequent destruction of the alveolar bone. It is one of the most common infectious diseases in humans, being the leading cause of tooth loss in adults. Recently, it has been shown that the receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and ...
Yutaro, Ando, Masayuki, Tsukasaki
openaire   +2 more sources

Relationship between serum RANKL and RANKL in bone

Osteoporosis International, 2011
It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology.
Findlay, D., Atkins, G.
openaire   +3 more sources

RANKL/RANK—beyond bones

Journal of Molecular Medicine, 2011
Receptor-activator of NF-κB ligand (TNFSF11, also known as RANKL, OPGL, TRANCE, and ODF) and its tumor necrosis factor (TNF)-family receptor RANK are essential regulators of bone remodeling, lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, and bone metastasis in cancer.
Hanada   +7 more
openaire   +2 more sources

Denosumab: Anti-RANKL antibody

Current Osteoporosis Reports, 2009
Denosumab (anti-receptor activator of nuclear factor-kappaB ligand antibody) is a novel agent, a fully human monoclonal antibody that inhibits osteoclastic-medicated bone resorption by binding to osteoblast-produced RANKL. By reducing RANKL binding to the osteoclast receptor RANK, bone resorption and turnover decrease.
openaire   +2 more sources

[RANKL vaccination].

Nihon rinsho. Japanese journal of clinical medicine, 2005
A therapeutic vaccine approach, targeting RANKL, can be used to inhibit bone destruction in pathological bone loss conditions such as osteoporosis, rheumatoid arthritis and bone metastasis. Compared to other therapeutic recombinant protein against pathological antigen such as monoclonal antibodies, soluble receptor or other antagonists, a vaccine needs
Takuo, Juji, Sakae, Tanaka
openaire   +1 more source

RANKLed About Fevers?

Science Signaling, 2009
RANKL-RANK signaling mediates the central fever response to inflammatory cytokines and plays a role in female thermoregulation.
openaire   +1 more source

RANKL and osteoimmunology in periodontitis

Journal of Bone and Mineral Metabolism, 2020
Periodontitis, one of the most common infectious diseases in humans, is characterized by inflammation of the periodontal tissue and subsequent destruction of the alveolar bone, which ultimately leads to tooth loss. Recently, it was revealed that the osteoclastic bone damage that occurs during periodontitis is dependent on the receptor activator of NF ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy